Contezolid (MRX-4/MRX-1)

Class: Oxazolidinone

Spectrum of activity:	Gram-positive
Details of activity:	MRSA (methicillin resistant Staphylococcus aureus) and VRE (vancomycin resistant Enterococcus sp.) ABSSI infections.
Institute where first reported:	MicuRx Pharmaceuticals, USA
Year first mentioned:	2014
Highest developmental phase:	Phase 3 (NCT06081361)
Development status:	Active (as of 2024)

Chemical structure(s):
Canonical SMILES:	C1=CN(CCC1=O)C2=C(C=C(C(=C2F)F)N3C[C@H](CNC4=NOC=C4)OC3=O)F
Isomeric SMILES:	C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
InChI:	InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
InChI Key:	SULYVXZZUMRQAX-NSHDSACASA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/25184541

External links:
Guide to Pharmacology:	contezolid
Main Source:	https://www.newtbdrugs.org/pipeline/compound/contezolid-mrx-4mrx-1
Citation:	http://aac.asm.org/content/58/4/2418.full